Description
Vagirux 10 Microgram Vaginal Tablets – Local Oestrogen Treatment for Menopause
Vagirux 10 Microgram Vaginal Tablets are a low-dose, locally applied hormone replacement therapy (HRT) used to treat vaginal atrophy caused by oestrogen deficiency after menopause.
During menopause, the body produces less oestrogen. This hormonal change can affect the tissues lining the vagina, making them thinner, drier and less elastic.
These changes can cause uncomfortable symptoms, including vaginal dryness, itching, irritation, soreness and discomfort during sexual intercourse.
Vagirux contains estradiol, a form of oestrogen that is chemically and biologically identical to the estradiol naturally produced by the body.
Unlike systemic HRT tablets, patches, gels and sprays, Vagirux is applied directly inside the vagina. It acts primarily on vaginal tissues, with only a small amount of estradiol absorbed into the bloodstream.
This makes Vagirux a targeted treatment for vaginal symptoms rather than a treatment for general menopause symptoms such as hot flushes and night sweats.
How Does Vagirux Work?
Oestrogen helps maintain the thickness, elasticity and moisture of the vaginal lining.
When oestrogen levels fall after menopause, vaginal tissues may become thinner, drier and more sensitive.
Vagirux delivers a low dose of estradiol directly to the vaginal tissues, helping to:
-
Improve the condition of the vaginal lining.
-
Restore moisture and reduce dryness.
-
Reduce irritation and soreness.
-
-
Reduce discomfort associated with vaginal atrophy.
The treatment also helps restore vaginal acidity towards its normal range, supporting the vaginal environment.
What Is Vaginal Atrophy?
Vaginal atrophy, often discussed as part of genitourinary syndrome of menopause (GSM), occurs when reduced oestrogen levels affect the tissues of the vagina and surrounding genital area.
Common symptoms include vaginal dryness, itching, irritation, soreness and discomfort during intercourse.
Some women may also experience urinary symptoms, although Vagirux is specifically licensed to treat vaginal atrophy due to postmenopausal oestrogen deficiency.
Who May Benefit from Vagirux?
Vagirux may be suitable for postmenopausal women experiencing vaginal symptoms caused by low oestrogen levels.
It may be considered for women who:
-
Experience persistent vaginal dryness.
-
Have vaginal itching or irritation associated with menopause.
-
Experience discomfort during intercourse due to vaginal dryness.
-
Prefer a local vaginal oestrogen treatment.
-
Need treatment for vaginal symptoms despite already using systemic HRT.
Suitability must be assessed by a prescriber, particularly where there is a history of hormone-sensitive cancer or unexplained vaginal bleeding.
Vagirux and Systemic HRT
Vagirux is a local vaginal oestrogen treatment.
It does not provide the same systemic oestrogen replacement as medicines such as Evorel, Oestrogel, Sandrena, Lenzetto or Zumenon.
Some women may be prescribed Vagirux alongside systemic HRT if vaginal symptoms persist despite their existing menopause treatment.
Because Vagirux delivers a very low dose of estradiol and systemic exposure generally remains within the normal postmenopausal range, additional progesterone is not normally required solely for Vagirux treatment, even in women who still have a womb.
However, women using systemic oestrogen HRT may still require progesterone for that separate treatment.
Key Benefits
-
Helps relieve menopause-related vaginal dryness.
-
Reduces vaginal irritation and discomfort.
-
Supports the health and moisture of vaginal tissues.
-
Contains a low dose of estradiol: 10 micrograms per tablet.
-
Acts locally inside the vagina.
-
Minimal systemic absorption compared with systemic HRT.
-
Simple maintenance schedule of twice-weekly application.
-
Includes a reusable applicator.
-
Can be prescribed alongside systemic HRT when appropriate.
-
Additional progesterone is not normally needed solely for this low-dose vaginal treatment.
-
Available in a 24-tablet pack.
Product Details
| Detail |
Information |
| Product Name |
Vagirux 10 Microgram Vaginal Tablets |
| Active Ingredient |
Estradiol (as estradiol hemihydrate) |
| Strength |
10 micrograms per tablet |
| Brand |
Vagirux |
| Manufacturer |
Gedeon Richter |
| Medicine Type |
Local vaginal oestrogen HRT |
| Form |
Film-coated vaginal tablets |
| Pack Size |
24 tablets |
| Applicator |
One reusable applicator |
| Main Use |
Postmenopausal vaginal atrophy |
| Initial Dosage |
One tablet daily for 14 days |
| Maintenance Dosage |
One tablet twice weekly |
| Administration |
Intravaginal only |
| Prescription Required |
Yes |
Directions
Always use Vagirux exactly as prescribed by your doctor or pharmacist.
Recommended Dosage
| Treatment stage |
Recommended dosage |
| Initial treatment |
One vaginal tablet daily for 14 days |
| Maintenance treatment |
One vaginal tablet twice weekly |
| Interval between maintenance doses |
3–4 days |
For example, during maintenance treatment, you may use one tablet every Monday and Thursday.
How to Use Vagirux Vaginal Tablets
-
Wash your hands before handling the tablet and applicator.
-
Remove the reusable applicator from its protective packaging.
-
Gently pull the applicator plunger backwards until it stops.
-
Remove one Vagirux tablet from its blister packaging.
-
Place the tablet firmly into the holder at the wider end of the applicator.
-
Carefully insert the applicator into the vagina until you feel gentle resistance.
-
Press the plunger to release the tablet inside the vagina.
-
Remove the applicator carefully.
-
Clean the applicator after use, following the instructions below.
-
Wash your hands thoroughly.
Important: Vagirux is intended for vaginal use only. Do not swallow the tablets.
How to Clean the Reusable Applicator
The applicator supplied with Vagirux can be reused for up to 24 applications by the same patient.
After each use:
-
Remove the plunger from the applicator tube.
-
Wash both parts with mild soap and warm tap water.
-
Rinse the inside and outside of the tube thoroughly.
-
-
Allow both parts to air-dry on a clean surface.
-
Reassemble the applicator when dry.
Do not share the applicator with another person. Replace it when starting a new pack, after 24 uses or if it becomes damaged.
What If You Miss a Dose?
If you forget to use Vagirux, insert the missed tablet as soon as you remember.
Do not use two tablets together to make up for a missed dose. Continue with your prescribed treatment schedule.
How Long Does a 24-Tablet Pack Last?
| Treatment stage |
Tablets used |
| First 14 days |
14 tablets |
| Remaining tablets |
10 tablets |
| Maintenance coverage from remaining tablets |
5 weeks |
For a new patient following the standard schedule, one 24-tablet pack provides approximately 7 weeks of treatment, including the initial two-week daily course.
For established patients using two tablets weekly, 24 tablets provide approximately 12 weeks of maintenance treatment.
Ingredients
Active Ingredient
Each vaginal tablet contains:
Estradiol 10 micrograms (as estradiol hemihydrate).
Other Ingredients
Tablet core:
Film coating:
Important: Vagirux contains lactose monohydrate. Patients with known allergies to any ingredient should consult their healthcare professional before use.
Side Effects
Like all medicines, Vagirux may cause side effects, although not everyone experiences them.
Common Side Effects
These may affect up to 1 in 10 users:
-
-
-
Vaginal bleeding or spotting.
-
-
Uncommon Side Effects
These may affect up to 1 in 100 users:
-
Vaginal fungal infection.
-
-
-
-
Increased blood pressure.
-
Other Reported Side Effects
-
Vaginal itching or burning.
-
Local allergic reactions.
-
-
-
-
Minor vaginal irritation or injury from the applicator.
Serious Side Effects
Although systemic absorption of estradiol is very low, important HRT precautions still apply.
Seek emergency medical attention if you experience:
-
Sudden chest pain or difficulty breathing.
-
Painful swelling in one leg.
-
Sudden facial weakness or difficulty speaking.
-
Severe allergic reactions, including swelling of the face, tongue or throat.
Contact your doctor promptly if you experience unexplained vaginal bleeding, particularly bleeding that starts after treatment has been established.
The risks associated with systemic HRT should not be assumed to apply at the same level to low-dose vaginal oestrogen.
Warnings
Do Not Use Vagirux If You:
-
Have, have previously had or are suspected of having breast cancer.
-
Have a known or suspected oestrogen-dependent cancer.
-
Have unexplained vaginal bleeding.
-
Have untreated endometrial hyperplasia.
-
Have or have previously had a blood clot.
-
Have certain inherited blood-clotting disorders.
-
Have active or recent arterial thromboembolic disease.
-
Have liver disease where liver function has not returned to normal.
-
-
Are allergic to estradiol or another ingredient.
Consult Your Doctor Before Treatment If You Have:
-
Uterine fibroids or endometriosis.
-
High blood pressure or diabetes.
-
Migraines or severe headaches.
-
Liver or gallbladder problems.
-
-
Heart or kidney conditions.
-
A family history of breast cancer.
-
An increased risk of blood clots.
-
Systemic lupus erythematosus.
-
A history of endometrial hyperplasia.
Additional Safety Information
Vaginal infections: Existing vaginal infections should be treated before starting Vagirux.
Breast cancer history: Women with a history of breast cancer, particularly those receiving endocrine treatment, require specialist advice before using vaginal oestrogen.
Unexplained bleeding: Any unexplained postmenopausal bleeding must be investigated.
Progesterone: Additional progesterone is not normally required solely for Vagirux because systemic estradiol exposure remains low.
Pregnancy and breastfeeding: Vagirux is not indicated during pregnancy or breastfeeding.
Regular reviews: Treatment should be reviewed periodically, with the benefits and risks assessed at least annually.
Long-term use: The endometrial safety of repeated or long-term treatment beyond one year is less certain, making follow-up important.
Reviews
There are no reviews yet.